Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Boston Scientific Moves Aggressively on Stent Graft

By HospiMedica staff writers
Posted on 06 Feb 2003
Under a series of agreements recently announced, Boston Scientific (Natick, MA, USA) has exclusive distribution rights to a new percutaneous stent graft and is to make an investment in the company that developed the stent graft. More...
Moreover, it has an exclusive option to acquire that company, which is TriVascular, Inc. (Santa Rosa, CA, USA). Terms of the agreements were not disclosed.

The stent graft is designed to improve the outcome of abdominal aortic aneurysm (AAA) therapy by being more durable and being deployed through the skin. The stent graft is delivered by a catheter small enough to allow a doctor to make a small puncture in the leg instead of an incision. TriVascular reduced the delivery system size by eliminating much of the metal required to keep other stent grafts open and replacing the metal with a polymer that is injected into channels within the graft during the procedure.

"We believe that TriVascular is the first to have developed a solution that substantially decreases the profile of the device down to a percutaneous range while also enhancing the durability of the graft,” said Paul La Violette, senior vice president and president, cardiovascular, Boston Scientific.





Related Links:
Boston Scientific
TriVascular

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.